We are live on ! Find out more
ALBO

Albireo Pharma Inc

Delisted

ALBO was delisted on the 2nd of March, 2023.

70 hedge funds and large institutions have $229M invested in Albireo Pharma Inc in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $101K | Put options by funds: $43K

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

26% more capital invested

Capital invested by funds: $181M → $229M (+$47.8M)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

1% more funds holding

Funds holding: 6970 (+1)

Holders
70
Holders Change
+1
Holders Change %
+1.45%
% of All Funds
1.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
28
Reduced
19
Closed
9
Calls
$101K
Puts
$43K
Net Calls
+$58K
Net Calls Change
+$388K
Name Holding Trade Value Shares
Change
Change in
Stake
PHK
76
Point72 Hong Kong
Hong Kong
-$1K -56 Closed
PMFA
77
Plante Moran Financial Advisors
Michigan
-$1K -49 Closed
SWM
78
Sugarloaf Wealth Management
Georgia
+$220 +11 New

ALBO Hedge Fund Activity: Q4 2019 in Review

70 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2019, worth a combined $229M — up 26% from $181M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALBO positions and 9 closed out — a net gain of 2 holders — while 28 added to existing stakes and 19 trimmed.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $4.87M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $4.6M.

  • 70 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2019, up from 69 in Q3 2019.
  • Funds reported $229M of Albireo Pharma Inc stock for Q4 2019, up 26% quarter-over-quarter.
  • 11 funds opened new Albireo Pharma Inc positions in Q4 2019 and 9 closed out, a net change of +2 holders.
  • The largest Albireo Pharma Inc buyer in Q4 2019 was ArrowMark Colorado Holdings, an estimated $4.87M added.
  • The largest Albireo Pharma Inc seller in Q4 2019 was TPG Group Holdings (SBS) Advisors, an estimated $4.6M sold.

Based on aggregated 13F filings for Q4 2019.